A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Top Cited Papers
- 6 August 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (6), 517-525
- https://doi.org/10.1056/nejmoa2016638
Abstract
Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown. We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was −2.4 percentage points (95% confidence interval, −7.0 to 2.2; P=0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.)Keywords
Funding Information
- University of Minnesota Foundation
- Jan and David Baszucki
- Alliance of Minnesota Chinese Organizations
- Minnesota Chinese Chamber of Commerce
This publication has 19 references indexed in Scilit:
- Epidemiology of Covid-19 in a Long-Term Care Facility in King County, WashingtonThe New England Journal of Medicine, 2020
- Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)Open Forum Infectious Diseases, 2020
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaThe New England Journal of Medicine, 2020
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Bi-directional differentiation of single bronchioalveolar stem cells during lung repairCell Discovery, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirology Journal, 2005